Elanco Logs 12% Q4 Revenue Growth and $0.02 Earnings Beat; Stock Rallies 6.6%
Elanco Animal Health shares have surged 137% over the past year and nearly 17% in 2026 after reporting Q4 revenue growth of 12% and a $0.02 earnings beat on an $0.11 basis. Management issued a robust full-year forecast, driving a 6.6% stock rally on the day of the quarter release.
1. Cramer Highlights Stock Comeback
Jim Cramer spotlighted Elanco Animal Health as a standout turnaround, emphasizing its 137% share gain over the last 12 months and nearly 17% rise since January as evidence of a compelling comeback in veterinary medicine.
2. Q4 Financial Results
In Q4, Elanco delivered 12% year-over-year revenue growth driven by strength in pet health and farm animal products, and reported $0.13 earnings per share, surpassing the $0.11 benchmark by $0.02.
3. Full-Year Outlook
Management provided a solid full-year forecast, projecting continued double-digit revenue growth and incremental margin expansion through fiscal 2026, reflecting confidence in sustained operational improvement.
4. Stock Market Reaction
Shares jumped 6.6% on the earnings announcement, extending gains to nearly 17% year-to-date and 137% over the past year, underscoring strong investor enthusiasm for Elanco’s growth trajectory.